Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The innovative eyedrop targets inflammation and pain following ocular surgery
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Under the deal, Quiver will receive an undisclosed advance payment and research support
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Subscribe To Our Newsletter & Stay Updated
